Payment overview · 2025
General Payments
$555.72
25 reported records · 9 companies
Healthcare provider profile · identity verified
Francisco A Albites
Allopathic & Osteopathic Physicians|Family Medicine · MIAMI, FL · NPI 1568687093
Verified facts
What the public records show
CMS Open Payments records show Francisco A Albites received $555.72 in general payments during 2025 across 25 reported records.
Exact Sciences Corporation accounted for 40.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $224.08 | 40.3% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $85.49 | 15.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $61.77 | 11.1% | 3 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $55.21 | 9.9% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $36.28 | 6.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.00 | 5.2% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $28.99 | 5.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.57 | 3.5% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $15.33 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $538.34 | 24 |
| Education | $17.38 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $224.08 | 10 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $55.21 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $41.34 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $41.10 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $36.28 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $36.28 | 2 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $29.00 | 1 | 2025 |
Source payment records
|
|||||
| OXLUMO Normalized: oxlumo |
Drug | Alnylam Pharmaceuticals Inc. | $28.99 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $25.37 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.57 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $15.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
37 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
37 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 326 | 103 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 260 | 86 |
| Amlodipine Besylate | Amlodipine Besylate | 258 | 82 |
| Metformin Hcl | Metformin Hcl | 238 | 77 |
| Losartan Potassium | Losartan Potassium | 222 | 69 |
| Lisinopril | Lisinopril | 168 | 52 |
| Omeprazole | Omeprazole | 155 | 58 |
| Simvastatin | Simvastatin | 145 | 50 |
| Levothyroxine Sodium | Levothyroxine Sodium | 122 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 112 | 40 |
| Famotidine | Famotidine | 110 | 36 |
| Gabapentin | Gabapentin | 107 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 107 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 104 | 31 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 104 | 39 |
| Diclofenac Sodium | Diclofenac Sodium | 101 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 95 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 90 | 34 |
| Montelukast Sodium | Montelukast Sodium | 84 | 28 |
| Alendronate Sodium | Alendronate Sodium | 66 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 58 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 55 | 20 |
| Lorazepam | Lorazepam | 52 | suppressed |
| Carvedilol | Carvedilol | 51 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 51 | 26 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 47 | 17 |
| Alprazolam | Alprazolam | 46 | 11 |
| Ezetimibe | Ezetimibe | 46 | 17 |
| Finasteride | Finasteride | 45 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 43 | 15 |
| Furosemide | Furosemide | 42 | 14 |
| Meloxicam | Meloxicam | 42 | 22 |
| Allopurinol | Allopurinol | 41 | 13 |
| Glimepiride | Glimepiride | 39 | 14 |
| Valsartan | Valsartan | 39 | 13 |
| Atenolol | Atenolol | 37 | 13 |
| Glipizide | Glipizide | 37 | 12 |
| Jardiance | Empagliflozin | 37 | 14 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 36 | 11 |
| Eliquis | Apixaban | 33 | 12 |
| Donepezil Hcl | Donepezil Hcl | 32 | 13 |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Temazepam | Temazepam | 31 | suppressed |
| Spironolactone | Spironolactone | 30 | 12 |
| Ibuprofen | Ibuprofen | 28 | 12 |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Latanoprost | Latanoprost | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Tadalafil | Tadalafil | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Folic Acid | Folic Acid | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 19 | suppressed |
| Potassium Chloride | Potassium Chloride | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | 14 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 18 | suppressed |
| Naproxen | Naproxen | 18 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 16 |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Prednisone | Prednisone | 16 | 11 |
| Trazodone Hcl | Trazodone Hcl | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Ciclopirox | Ciclopirox | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Ozempic | Semaglutide | 14 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $555.72 · 25 records | Exact Sciences Corporation | AIRSUPRA, Brinsupri, Leqembi, MOUNJARO, OFEV, OTEZLA, OXLUMO, REPATHA, The Cologuard Plus Collection Kit, XIFAXAN, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error